Introduction
============

Sepsis remains a significant medical problem. TNFα is a central cytokine in sepsis pathophysiology. We conducted a phase IIa trial in patients with severe sepsis to assess the safety and tolerability of an intravenously infused ovine-derived polyclonal anti-TNFα Fab fragment (AZD9773).

Methods
=======

This was a double-blind, placebo-controlled, dose-escalation trial (NCT00615017) with 2:1 randomisation (active:placebo). Two single-dose cohorts (50 units/kg and 250 units/kg) and three multiple-dose cohorts (250 units/kg followed by nine doses of 50 units/kg every 12 hours, 500 units/kg followed by nine doses of 100 units/kg, 750 units/kg followed by nine doses of 250 units/kg) were studied. Safety was assessed by monitoring adverse events (AEs), mortality, and laboratory safety measures, including formation of human anti-sheep antibodies (HASA) and their association with AEs.

Results
=======

A total of 70 patients were studied. The mean age was 56 years, 46% were male, and the mean APACHE II score was 26. About 50% of patients had two organ failures (both respiratory and cardiovascular). Multiple doses of AZD9773 reduced circulating TNFα towards the limit of detection in most patients throughout the 5 days of dosing. The most common serious AEs were mainly related to the underlying illness and included: sepsis, pneumonia, septic shock and respiratory failure across all groups. Table [1](#T1){ref-type="table"} summarises the safety outcomes. Development of HASA did not appear to be associated with either decreased TNFα reduction or specific AEs.

###### 

Safety outcomes with AZD9773 administration

                                                 Single-dose cohorts combined (*n*= 17)   Multiple-dose cohorts combined (*n*= 30)   Placebo (*n*= 23)
  ---------------------------------------------- ---------------------------------------- ------------------------------------------ -------------------
  Mortality, *n*(%)                              6 (35%)                                  7 (23%)                                    6 (26%)
  Any treatment-emergent AEs                     17 (100%)                                27 (90%)                                   23 (100%)
  Treatment-emergent AEs related to study drug   2 (12%)                                  7 (23%)                                    10 (43%)
  Patients with any serious AEs                  9 (53%)                                  14 (47%)                                   13 (57%)

Conclusions
===========

Administration of AZD9773 in patients with severe sepsis reduced circulating TNFα levels and had a safety profile similar to placebo administration. A larger randomised phase IIb clinical trial (NCT01145560) is ongoing to further characterise the safety and efficacy of AZD9773 in patients with severe sepsis.
